Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Total Liabilities (2023 - 2025)

Historic Total Liabilities for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $214.0 million.

  • Monte Rosa Therapeutics' Total Liabilities rose 9521.82% to $214.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.0 million, marking a year-over-year increase of 9521.82%. This contributed to the annual value of $215.8 million for FY2024, which is 7332.32% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Total Liabilities stood at $214.0 million, which was up 9521.82% from $91.5 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Total Liabilities peaked at $215.8 million during Q4 2024, and registered a low of $65.0 million during Q2 2023.
  • Moreover, its 3-year median value for Total Liabilities was $114.2 million (2024), whereas its average is $118.6 million.
  • Within the past 5 years, the most significant YoY rise in Monte Rosa Therapeutics' Total Liabilities was 9521.82% (2025), while the steepest drop was 2338.94% (2025).
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Total Liabilities stood at $124.5 million in 2023, then soared by 73.32% to $215.8 million in 2024, then fell by 0.83% to $214.0 million in 2025.
  • Its last three reported values are $214.0 million in Q3 2025, $91.5 million for Q2 2025, and $118.0 million during Q1 2025.